GLP-1 Peptide Atlas, by Delfa

CompletedPhase NAResults posted

Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus

Lead sponsor

University of Athens

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Cardiovascular disease, Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes

Key I/E criterion

•BMI ≥30

Primary endpoints

•Differences in Pulse Wave Velocity•Differences in Augmentation Index•Differences in Coronary Flow Reserve

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03010683

Org study IDGLP1-DM-ATTIKON

Timeline

Milestones

Study first posted2017-01-05estimated

Last update posted2021-03-05actual

Results first posted2021-03-05actual

Study start2015-11 (month precision)

Primary completion2017-06actual (month precision)

Study completion2017-12actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Cardiovascular diseaseObesity / overweightPrediabetes / glucose intoleranceType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Patients with type 2 diabetes mellitus (T2DM) without coronary artery disease (CAD)

•Patients with T2DM and CAD.

•Obese patients (BMI >30 Kg/m²) with abnormal oral glucose tolerance test (OGTT)

Exclusion criteria

•valvular heart disease

•congestive heart failure

•peripheral vascular disease

•liver or kidney failure

•history of alcohol or drug abuse

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Other (unclassified)

Cardiometabolic biomarkers

10 endpoints

Primary/registry result/low confidence

Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.

Time frame:Baseline, 3 months, 6 months and 12 months

change from baseline, improvement

Posted result

Group	Value (mean), m/s	95% CI
LiraglutideBaseline	11.8	—
3 months	11.6	—
6 months	10.3	—
12 months	10.5	—
MetforminBaseline	11.2	—
3 months	11.5	—
6 months	11	—
12 months	10.8	—

Primary/registry result

Differences in Augmentation Index at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.

Time frame:Baseline, 3 months, 6 months, and 12 months.

change from baseline, improvement

Posted result

Group	Value (mean), percentage of the central pulse pressure	95% CI
LiraglutideBaseline	18	-1 – 31
3 months	15.8	-2 – 29
6 months	13	-2 – 31
12 months	13.9	-1 – 32
MetforminBaseline	14	-9 – 24
3 months	13.6	-6 – 25
6 months	15	-8 – 24
12 months	15.3	-6 – 24

Primary/registry result/low confidence

Differences in Coronary Flow Reserve at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.

Time frame:Baseline, 3 months, 6 months, and 12 months.

change from baseline, improvement

Primary/registry result/low confidence

Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.

Time frame:Baseline, 3 months, 6 months, and 12 months.

change from baseline, improvement

Posted result

Group	Value (mean), micrometers	95% CI
LiraglutideBaseline	2.1	—
3 months	2.07	—
6 months	2.5	—
12 months	2.04	—
MetforminBaseline	2.13	—
3 months	2.15	—
6 months	2.13	—
12 months	2.10	—

Primary/protocol endpoint

Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.

Time frame:Baseline, 3 months, 6 months and 12 months

change from baseline, improvement

Primary/protocol endpoint

Differences in Augmentation Index at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.

Time frame:Baseline, 3 months, 6 months, and 12 months.

change from baseline, improvement

Primary/protocol endpoint

Differences in Coronary Flow Reserve at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.

Time frame:Baseline, 3 months, 6 months, and 12 months.

change from baseline, improvement

Primary/protocol endpoint/low confidence

Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.

Time frame:Baseline, 3 months, 6 months, and 12 months.

change from baseline, improvement

Secondary/registry result

Endothelial Glycocalyx and Pulse Wave Velocity.

Time frame:Baseline, 3 months, 6 months, and 12 months.

PBR PWV correlation

ratio, descriptive

Posted result

Group	Value (number), Pearson correlation coefficient (r)	95% CI
LiraglutideBaseline	0.39	—
3 months	0.36	—
6 months	0.32	—
12 months	0.44	—
MetforminBaseline	0.35	—
3 months	0.32	—
6 months	0.29	—
12 months	0.37	—

Secondary/protocol endpoint/low confidence

Endothelial Glycocalyx and Pulse Wave Velocity.

Time frame:Baseline, 3 months, 6 months, and 12 months.

change from baseline, improvement

Other (unclassified)

2 endpoints

Secondary/registry result/low confidence

Endothelial Glycocalyx and Coronary Flow Reserve.

Time frame:Baseline, 3 months, 6 months, and 12 months.

descriptive

Secondary/protocol endpoint/low confidence

Endothelial Glycocalyx and Coronary Flow Reserve.

Time frame:Baseline, 3 months, 6 months, and 12 months.

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Metformin monotherapy for adults with type 2 diabetes mellitus.
The Cochrane database of systematic reviews2020 Jun 5PMID32501595doi:10.1002/14651858.CD012906.pub2via clinicaltrials gov reference derived + pubmed nct search
Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Cardiovascular diabetology2018 Jan 8PMID29310645doi:10.1186/s12933-017-0646-zvia clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.